Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracoronary KAI-9803 in Acute STEMI
NCT00093197Phase 2Completed
- Sponsor
- KAI Pharmaceuticals
- Start
- Sep 2004
- Primary completion
- Oct 2006
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of delcasertib in ST elevation myocardial infarction (STEMI) (5 arms), sponsored by KAI Pharmaceuticals. Primary endpoints: Number of participants with adverse events at 30 days and Number of participants with major cardiac events at 6 months. Started Sep 2004; status: completed.
02
Drugs
delcasertib
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT00093197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093197.